CD4 and neoplasm: (4) T cell‐targeted therapies: Enhancing tumor antigen secretion and presentation, such as through tumor vaccines or cytokine therapies, could effectively activate the large population of dormant immune cells (CD8+/CD4+ bystander T cells) within the HRP TIME.